Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
View/ Open
Issue Date
2020-07-21Author
Paton, Kelly F.
Biggerstaff, Andrew
Kaska, Sophia
Crowley, Rachel S.
La Flamme, Anne C.
Prisinzano, Thomas E.
Kivell, Bronwyn M.
Publisher
Frontiers Media
Type
Article
Article Version
Scholarly/refereed, publisher version
Rights
© 2020 Paton, Biggerstaff, Kaska, Crowley, La Flamme, Prisinzano and Kivell.
Metadata
Show full item recordAbstract
In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been highlighted as a key cellular mechanism to reduce the side effects of KOPr agonists. The present study investigated KOPr signaling bias and the acute antinociceptive effects and side effects of two novel analogs of SalA, 16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias, whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious. 16-Ethynyl SalA and 16-Bromo SalA both had a longer duration of action in the warm water tail-withdrawal assay, and 16-Ethynyl had greater antinociceptive effect in the hot-plate assay, compared to SalA. In the intraplantar 2% formaldehyde test, 16-Ethynyl SalA and 16-Bromo SalA significantly reduced both nociceptive and inflammatory pain-related behaviors. Moreover, 16-Ethynyl SalA and 16-Bromo SalA had no anxiogenic effects in the marble burying task, and 16-Bromo SalA did not alter behavior in the elevated zero maze. Overall, 16-Ethynyl SalA significantly attenuated acute pain-related behaviors in multiple preclinical models, while the biased KOPr agonist, 16-Bromo SalA, displayed modest antinociceptive effects, and lacked anxiogenic effects.
Description
This work is licensed under a Creative Commons Attribution 4.0 International License.
Collections
Citation
Paton, K. F., Biggerstaff, A., Kaska, S., Crowley, R. S., La Flamme, A. C., Prisinzano, T. E., & Kivell, B. M. (2020). Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain. Frontiers in neuroscience, 14, 765. https://doi.org/10.3389/fnins.2020.00765
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.